Literature DB >> 26430348

System of adverse drug reactions reporting: What, where, how, and whom to report?

Vivekanandan Kalaiselvan1, Pranay Kumar1, Prabhakar Mishra1, Gyanendra Nath Singh1.   

Abstract

Entities:  

Year:  2015        PMID: 26430348      PMCID: PMC4578206          DOI: 10.4103/0972-5229.164819

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


× No keyword cloud information.
Sir, The continuous progress in medical and pharmaceutical sciences has made the availability of pharmaceutical products in the Indian market to prevent and control of several disease conditions. Irrespective of the benefits associated with the use of medicines adverse effects associated with them has emerged the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base. World Health Organization (WHO) defined ADR as “A response which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function.”[1] To improve public health, the safe use of medicine must be monitored through an effective pharmacovigilance (PV) system. PV is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other possible drug-related problems.[2] Indian Pharmacopoeia Commission (IPC), Ghaziabad is functioning as a National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI). One Hundred and fifty ADR monitoring centres (AMCs) were established in various medical institutions/hospitals across India to monitor and collect ADR reports under NCC-PvPI.[3]

What to Report

PvPI encourages all types of suspected ADRs reporting whether they are known, unknown, serious, or nonserious, frequent, or rare regardless of an established causal relationship between a drug and the reaction. ADRs related with the use of allopathic medicines, vaccines, traditional medicines, medical devices, contrast media, etc., can be reported.

Where to Report

All healthcare professionals (clinicians, dentists, pharmacists, nurses) and patient/consumers can report ADRs to NCC or AMCs. The pharmaceutical companies can also send individual case safety reports for their product to NCC.

How to Report

Suspected ADR reporting forms [Figure 1] for healthcare professionals and consumers are available on the website of IPC to report ADR. To remove language barrier in ADR reporting, the consumer reporting form [Figure 2] are made available in 10 vernacular languages (Hindi, Tamil, Telugu, Kannada, Bengali, Gujarati, Assamese, Marathi, Oriya, and Malayalam). ADRs can be also reported via PvPI helpline number (18001803024) on weekdays from 9:00 am to 5:30 pm.[3] The mobile Android application for ADR reporting has also been made available to the public.
Figure 1

Suspected adverse drug reaction reporting form

Figure 2

Medicines side effect reporting form (for consumers)

Suspected adverse drug reaction reporting form Medicines side effect reporting form (for consumers)

Whom to Report

A reporter can send filled ADR reporting form directly to NCC or their nearest AMC. In case of AMC, these reports are confirmed by healthcare professionals and entered into Vigiflow and sent to NCC for further assessment.[4] These reports are then finally reviewed at NCC and committed to WHO-Uppsala Monitoring Centre. The obtained information is entered in the drug safety database, analyzed, and assessed by the experts to identify new signals.[5] The submitted ADR report does not have any legal implication on the reporters. The patients’ identity are held in strict confidence and protected to the fullest extent. Therefore, healthcare providers are encouraged to report ADRs for better understanding of the risk associated with the use of medicines and to safeguard the health of Indian population.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  2 in total

1.  Status of documentation grading and completeness score for Indian individual case safety reports.

Authors:  Kalaiselvan Vivekanandan; Kumar Rishi; Thota Prasad; Tripathi Arunabh; G N Singh
Journal:  Indian J Pharmacol       Date:  2015 May-Jun       Impact factor: 1.200

2.  Adverse drug reactions reporting culture in Pharmacovigilance Programme of India.

Authors:  Vivekanandan Kalaiselvan; Thota Prasad; Akanksha Bisht; Surinder Singh; Gyanendra Nath Singh
Journal:  Indian J Med Res       Date:  2014-10       Impact factor: 2.375

  2 in total
  7 in total

1.  An observational study to assess the possibility of patient participation in implementing pharmacovigilance in a busy tertiary care hospital.

Authors:  A Tejus; A G Mathur; R Vishnuprasad; Akansha Singh; Sapna Pradhan
Journal:  Med J Armed Forces India       Date:  2019-12-16

2.  A Qualitative Study of Stakeholders' Views on Pharmacovigilance System, Policy, and Coordination in Pakistan.

Authors:  Muhammad Akhtar Abbas Khan; Saima Hamid; Shahzad Ali Khan; Mariyam Sarfraz; Zaheer-Ud-Din Babar
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

3.  Another feather in the crown of medical safety and ethics in India.

Authors:  Krishnan Vengadaragava Chary
Journal:  Perspect Clin Res       Date:  2017 Jul-Sep

4.  Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.

Authors:  Miaomiao Yang; Hongqiu Pan; Lihuan Lu; Xiaomin He; Hongbo Chen; Bilin Tao; Wenpei Liu; Honggang Yi; Shaowen Tang
Journal:  BMJ Open       Date:  2019-03-30       Impact factor: 2.692

Review 5.  A global comparison of implementation and effectiveness of materiovigilance program: overview of regulations.

Authors:  Deeksha Joshi; Ishita Sharma; Saurabh Gupta; Thakur Gurjeet Singh; Sonia Dhiman; Abhimanyu Prashar; Monica Gulati; Bimlesh Kumar; Sukriti Vishwas; Dinesh Kumar Chellappan; Gaurav Gupta; Niraj Kumar Jha; Piyush Kumar Gupta; Poonam Negi; Kamal Dua; Sachin Kumar Singh
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-13       Impact factor: 4.223

Review 6.  Pharmacovigilance in radiopharmaceuticals.

Authors:  Rishi Kumar; Vivekanandan Kalaiselvan; Rakesh Kumar; Ravendra Verma; Gyanendra Nath Singh
Journal:  Indian J Nucl Med       Date:  2016 Apr-Jun

Review 7.  Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.

Authors:  Jai Prakash; Raghav Sachdeva; Tarani Prakash Shrivastava; C V Jayachandran; Aseem Sahu
Journal:  Indian J Pharmacol       Date:  2021 Mar-Apr       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.